TY - JOUR T1 - A model based on a high-resolution flux matrix explains the spread of diseases in a spatial network and the effect of mitigation strategies JF - medRxiv DO - 10.1101/2021.12.22.21268059 SP - 2021.12.22.21268059 AU - Guillaume Le Treut AU - Greg Huber AU - Mason Kamb AU - Kyle Kawagoe AU - Aaron McGeever AU - Jonathan Miller AU - Reuven Pnini AU - Boris Veytsman AU - David Yllanes Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/12/27/2021.12.22.21268059.abstract N2 - Propagation of an epidemic across a spatial network of communities is described by a variant of the SIR model accompanied by an intercommunity infectivity matrix. This matrix is estimated from fluxes between communities, obtained from cell-phone tracking data recorded in the USA between March 2020 and February 2021. We have applied this model to the 2020 dynamics of the SARS-CoV-2 pandemic. We find that the numbers of susceptible and infected individuals predicted by the model agree with the reported cases in each community by fitting just one global parameter representing the frequency of interaction between individuals. The effect of “shelter-in-place” policies introduced across the USA at the onset of the pandemic is clearly seen in our results. We then consider the effect that alternative policies would have had, namely restricting long-range travel. We find that this policy is successful in decreasing the epidemic size and slowing down the spread, at the expense of a substantial restriction on mobility as a function of distance. When long-distance mobility is suppressed, this policy results in a traveling wave of infections, which we characterize analytically. In particular, we show the dependence of the wave velocity and profile on the transmission parameters. Finally, we discuss a policy of selectively constraining travel based on an edge-betweenness criterion.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors acknowledge the generous support of the Chan Zuckerberg Initiative and Chan Zuckerberg Biohub. D.Y. acknowledges support by MINECO (Spain) through Grant No. PGC2018-094684-B-C21, partially funded by the European Regional Development Fund (FEDER).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at https://github.com/czbiohub/epidemiology_flux_model and upon reasonable request to the authors. https://github.com/czbiohub/epidemiology_flux_model ER -